VIR - Lawmakers set to announce $10 billion additional funding for U.S. COVID response - WaPo

Congressional negotiators have agreed on a $10 billion additional funding for U.S. COVID-19 response, and the deal is expected to be announced on Monday, The Washington Post reported citing two people with knowledge of the matter.   The package provides funds for the purchase of more therapeutics, tests, vaccines, and other supplies.   However, the lawmakers have failed to reach an agreement for a $15 billion package that included $5 billion for the global response which President Biden previously said was critical to keep Americans safe from the threat of new variants. Developers of COVID-19 antibody therapies: Gilead (GILD), Eli Lilly (LLY), Vir Biotechnology (VIR)/ GlaxoSmithKline (GSK), Regeneron (REGN). The makers of COVID-19 pills: Pfizer (PFE), Merck (MRK). COVID-19 vaccine makers: Pfizer (PFE)/ BioNTech (BNTX), Moderna (MRNA), Johnson & Johnson (JNJ) Last month, the Biden administration warned that the government was at risk of running out of COVID-19 antibody therapies as early as May unless Congress

For further details see:

Lawmakers set to announce $10 billion additional funding for U.S. COVID response - WaPo